Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?

Digestive and Liver Disease

Volumn 38, Issue 2, 2006, Pages 119-124

  Guadagnino, V ^a   Trotta, M P ^b   Carioti, J ^a   Caroleo, B ^a   Antinori, A ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Depression; HCV infection; Intravenous drug user; Peg interferon; Treatment adherence

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ADULT; ANOREXIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; INTRAVENOUS DRUG ABUSE; MALE; PAIN; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PRURITUS; QUESTIONNAIRE; RATING SCALE; SELF REPORT; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VOMITING; COMORBIDITY; PSYCHOLOGICAL ASPECT; SUBSTANCE ABUSE;

ADULT; ANTIVIRAL AGENTS; COMORBIDITY; DEPRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33745353681     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.10.008     Document Type: Article

References (24)

1. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002;36:S3-15.
2. Schaefer M., Heinz A., and Backmund M. Treatment of chronic Hepatitis C in patients with drug dependence: time to change the rules?. Addiction 99 (2004) 1167-1175
3. Mauss S., Berger F., Goelz J., Jacob B., and Schmutz G. A prospective controlled study of interferon-based therapy of chronic Hepatitis C in patients on methadone maintenance. Hepatology 40 (2004) 120-124
4. Davis G.L., Wong J.B., McHutchinson J.G., Manns M.P., Harvey J., and Albretch J. Early virologic response to treatment with peg-interferon alpha-2b plus ribavirin in patients with chronic HCV infection. Hepatology 38 (2003) 645-652
5. Radloff L. The CES-D Scale: a self-report scale for research in the general population. Appl Psychol Meas 1 (1977) 385-401
6. Fava G.A. Assessing depressive symptoms across cultures: Italian validation of the CES-D self-rating scale. J Clin Psychol 39 (1983) 249-251
7. Ensel W. Measuring depression: the CES-D Scale. In: Lin N., Dean A., and Ensel W. (Eds). Social support, life events and depression (1986), Academic Press, Orlano 51-70
8. Jonshon M.E., Fisher D.G., Fenaughty A., and Theno S.A. Hepatitis C virus and depression in drug users. Am J Gastrenterol 93 (1998) 785-789
9. El- Serag H.B., Kunik M., Richardoson P., and Rabeneck L. Psychiatric disorders among veterans with Hepatitis C infection. Gastroenterology 123 (2002) 476-482
10. Murri R., Ammassari A., Gallicano K., De Luca A., Cingolani A., Jacobson D., et al. Patient-reported non-adherence is related to protease inhibitor levels. J Acquir Immune Defic Syndr 24 (2000) 123-128
11. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic Hepatitis C. N Engl J Med 339 (1998) 1485-1492
12. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alpha-2b alone or in combination with ribavirin for treatment of relapse of chronic Hepatitis C. N Engl J Med 339 (1998) 1493-1499
13. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., et al. Adherence and mental side effect during Hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 37 (2003) 443-451
14. Fried M.W. Side effects of therapy of Hepatitis C and their management. Hepatology 36 (2002) S237-S244
15. Zickmund S., Hillis S.L., Barnett M.J., Ippolito L., and LaBrecque D.R. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39 (2004) 999-1007
16. Di Matteo M.R., Lepper H.S., and Croghan T.W. Depression is a risk factor for non-compliance with medical treatment: meta-analysis of the effect of anxiety and depression on patient adherence. Arch Intern Med 160 (2000) 2101-2107
17. Starace F., Ammassari A., Trotta M.P., Murri R., De Longis P., Izzo C., et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31 Suppl. 3 (2002) S136-S139
18. Ammassari A., Antinori A., Aloisi M.S., Trotta M.P., Murri R., Bartoli L., et al. The relationship of depressive symptoms, neurocognitive impairment and HAART adherence among HIV-infected persons. Psychosomatics 45 (2004) 394-402
19. Backmund M., Meyer k., Von Zielonka M., and Eichenlaub D. Treatment of Hepatitis C infection in injection drug users. Hepatology 34 (2001) 188-193
20. Schaefer M., Schwaiger M., Garkisch A.S., Pich M., Hinzpeter A., Uebelhack R., et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic Hepatitis C. J Hepatol 42 (2005) 793-798
21. Ammassari A., Murri R., Pezzotti P., Trotta M.P., Ravasio L., De Longis P., et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 28 (2001) 445-449
22. Heath K.V., Singer J., O'Shaughnessy M.V., Montaner J.S., and Hogg R.S. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 31 (2002) 211-217
23. Broers B., Helbling B., Francois A., Schmid P., Chuard C., Hadengue A., et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute Hepatitis C. J Hepatol 42 (2005) 323-328
24. Justice A.C., Rabeneck L., Hays R.D., Wu A.W., Bozzette S., and Outcomes Committee of the AIDS Clinical Trial Group. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J Acquir Immune Defic Syndr 21 (1999) 126-133